With more than 30 approved monoclonal antibody therapeutics on the market and hundreds of candidate molecules in the clinical and pre-clinical stages of testing, the development of therapeutic antibodies is a blooming field enjoying its Renaissance age. The disease indications for antibody therapeutics are rapidly diversifying beyond the two primary areas of oncology and inflammatory diseases, as exemplified by an increasing number of clinical programs in infectious diseases, Alzheimer’s Disease, and metabolic diseases. The modulation of novel targets and disease pathways are being actively pursued with antibody therapeutic candidates, and new modalities as well as innovative therapeutic approaches are being intensely explored to complement the traditional monoclonal antibody therapeutics. Despite the current success of the field, significant challenges remain, particularly on how to effectively translate antibody therapeutic candidates from research into the clinic. At this symposium, we will highlight how emerging scientific understanding of diseases and cutting-edge pharmaceutical technologies are applied to the development of next-generation antibody therapeutics. We intend to lay down the framework for addressing the translational challenges and discuss the future direction of the field.
Reception to follow.
|Nonmember (Student / Postdoc / Resident / Fellow)
Mission Partner support for the Frontiers of Science program provided by